Navigation Links
NIH Funds Synedgen to Develop a New Drug to Improve Airway Clearance
Date:9/27/2013

to tackle biofilms and sputum, reducing their cohesion and viscosity to allow the patient to clear them both. Our preliminary data demonstrates that our polymeric drug both reduces the viscosity of CF sputum and improves sputum mobility in vitro, and separately loosens biofilms,” stated Synedgen President Shenda Baker. “We hypothesize the drug will have significant synergistic activity with traditional antibiotics, and are eager to explore the magnitude and duration of these effects in mucus, biofilms, and in combination.”

In other studies of pathogenic infection and mucosal surface damage, this new drug has been shown to reduce inflammation at the surface. Since cystic fibrosis is a disease severely affected by airway inflammation, future studies will also examine the drug’s potential additional role in mitigating pulmonary inflammation.

“The preliminary data are extremely exciting,” stated Dr. Steven Rowe, “and could provide a new avenue to address mucus stasis in CF lung disease, potentially improving lung health.”

Preliminary results from these studies will be presented in October at the 27th Annual North American Cystic Fibrosis Conference. Synedgen hopes its new drug will make the sputum flow more freely, break up pathogenic biofilms and also enhance activity of standard antibiotics, providing a new and highly effective pulmonary treatment to help CF patients breathe more easily and combat lung infections.

Research reported in this press release was supported by the National Heart Lung and Blood Institute of the National Institutes of Health under award number 1R43HL118867. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product develop
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. QB3-Industry Biotech Startup Partnership Funds Two Projects
3. German Academic Exchange Service funds international project on spintronics
4. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
5. Express Diagnostics to Raise Funds for American Cancer Society During Blue Earth’s Giant Days Parade
6. Kitware Receives Funds from U.S. Air Force Research Lab to Extend the Bender Toolkit for Anatomical Model Repositioning
7. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
10. Scarred for Life? Synedgen Hopes Not
11. Synedgen's Synoplex® is Headed to the Lewa Wildlife Conservancy in Kenya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 The College ... first private college in the Mid-Hudson Region to be ... now begin accepting applications from qualified “high-technology” businesses that ... are very pleased to have been selected for the ... Cuomo’s transformative initiative to stimulate economic development in New ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary ... by the Jeffrey Epstein VI Foundation , have shown ... identified for elimination. These aggressive cells are the driver mutations ... topological map of what to look for when examining tumors, ... tumor cells can be extracted from biopsy, it,s very difficult ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... cells are not pampered pushovers. O,Reilly et al. report ... molding their environment to control their division and differentiation., ... cradle them in a structure called the niche. The ... their behavior, determining whether they reproduce and specialize. The ...
... from Chinese Health Authorities to Launch Final ... Clinical Trial for ... Inc.,today announced the appointment of Dr. Geert Cauwenbergh as Chief ... Cauwenbergh has been assisting RHEI Pharmaceuticals since August 1, 2008,in ...
... 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), ... and marketing biopharmaceutical products,primarily in China, announces that ... Morgan Stanley Global Healthcare Unplugged Conference in New,York ... A copy of the latest investor presentation ...
Cached Biology Technology:RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 2RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 3RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 4
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... of Health has awarded the Oklahoma Medical Research Foundation ... on anthrax and the bacteria,s effects on humans. ... and his colleagues have studied the human immune response ... for Human Immunology. The original funding came soon after ... heels of the terrorist attacks of Sept. 11, 2001. ...
(Date:8/20/2014)... athletes who have suffered concussions ready to return to ... that high school athletes who head back on the ... significant regression in their abilities to simultaneously walk and ... in changes in their balance and/or altered walking speed, ... the 12 had returned to activity in less than ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Previously unknown molecules and regulatory pathways in human ... effort of the Medizinische Poliklinik, Munich, the University ... Research Center, sanofi-aventis, and Genomatix Software GmbH. , ... the National Academy of Sciences of the United ...
... of the biggest problems in fighting breast cancer is ... , Researchers at the University of Michigan hope to ... for the presence of metabolites associated with breast cancer. ... award, which funds promising, high-risk, high reward research proposals ...
... from two universities in Italy and Virginia Tech in ... protein that is responsible for the production xanthurenic acid ... plays a key role in the sexual reproduction of ... Interfering with the formation of XA could be an ...
Cached Biology News:Researchers win money to develop breath test to detect breast cancer 2Oxidation defense in mosquitoes benefits malaria parasite 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... and BR4i refrigerated multifunction centrifuges are equally capable ... a low sound level with a large range ... AUTO-LOCK rotor exchange system without tools ensures that ... seconds. Instant rotor exchange (5 sec.) ...
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
Biology Products: